Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-10-09
2007-10-09
Rawlings, Stephen L. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C536S023100, C536S023500
Reexamination Certificate
active
10859643
ABSTRACT:
A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.
REFERENCES:
patent: 5001225 (1991-03-01), Taylor
patent: 6323321 (2001-11-01), Bühring
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 2002/0137139 (2002-09-01), Byatt et al.
patent: 2003/0165505 (2003-09-01), Challita-Eid et al.
patent: 2003/0191073 (2003-10-01), Challita-Eid et al.
patent: 2003/0206905 (2003-11-01), Challita-Eid et al.
patent: 2005/0055733 (2005-03-01), Sun et al.
patent: 2005/0265921 (2005-12-01), Challita-Eid et al.
patent: 2005/0265924 (2005-12-01), Challita-Eid et al.
patent: 2006/0002993 (2006-01-01), Challita-Eid et al.
patent: 2006/0275211 (2006-12-01), Challita-Eid et al.
patent: 2007/0004913 (2007-01-01), Challita-Eid et al.
patent: WO 99/60164 (1999-11-01), None
patent: WO 00/21990 (2000-04-01), None
patent: WO 01/57272 (2001-08-01), None
patent: WO 01/57273 (2001-08-01), None
patent: WO 01/57274 (2001-08-01), None
patent: WO 01/57275 (2001-08-01), None
patent: WO 01/57276 (2001-08-01), None
patent: WO 01/57277 (2001-08-01), None
patent: WO 01/57278 (2001-08-01), None
patent: WO 01/60860 (2001-08-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/86003 (2001-11-01), None
patent: WO 02/79411 (2002-10-01), None
patent: WO 03/004514 (2003-01-01), None
patent: WO 03/016475 (2003-02-01), None
patent: WO 03/040340 (2003-05-01), None
Bühring et al., Blood 94(7):2343-2356 (1999).
Bühring et al., Blood 97(10):3303-3305 (2001).
Burgess et al., Journal of Cell Biology 111:2129-2138 (1990).
Coleman, Research in Immunology 145:33-36 (1994).
Jin-Hua et al., Genomics 45(2):412-415 (1997).
Lazar et al., Molecular and Cellular Biology 8(3):1247-1252 (1988).
Lederman et al., Molecular Immunology 28:1171-1181 (1991).
Li et al., Proc Natl Acad Sci USA 77:3211-3214 (1980).
Paul (Ed.), Fundamental Immunology, 3rd ed., p. 242 (1993).
Reiger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlag, Berlin (1976).
Schwartz et al., Proc Natl Acad Sci USA 84:6408-6411 (1987).
Deissler et al., Journal of Biological Chemistry (1995) 270(17):9849-9855.
Colbern et al., J. Inorg. Biochem. (1999) 77:117-120.
Houghton and Scheinberg, Seminars in Oncology (1986) 13:165-179.
Andoh et al., “Genomic structure and promoter analysis of the ecto-phosphodiesterase I gene (PDNP3) expressed in glial cells,” Biochimica et Biophysica Acta (1999) 1446(3):213-224.
Bollen et al., “Nucleotide pyrophosphatases/phosphodiesterases on the move,” Critical Reviews in Biochemistry and Molecular Biology (2000) 35(6):393-432.
Maurice et al., “Characterization of rat hepatocyte plasma membrane domains by monoclonal antibodies,” European Journal of Cell Biology (1985) 39(1):122-129.
Maurice et al., “Biosynthesis and intracellular transport of a bile canalicular plasma membrane protein: studies in vivo and in the perfused rat liver,” Hepatology (1994) 19(3):648-655.
Scott et al., “Biochemical and molecular identification of distinct forms of alkaline phosphodiesterase I expressed on the apical and basolateral plasma membrane surfaces of rat hepatocytes,” Hepatology (1997) 25(4):995-1002.
Dennis, Nature (2006) 442:739-741.
Srivastava, Nature Immunology (2000) 1(5):363-366.
Jain, Scientific American (1994) 271:58-65.
Dillman, Annals of Internal Medicine (1989) 111:592-603.
Weiner, Seminars in Oncology (1999) 26(Suppl. 12):41-50.
NCBI Accession No. NP—004439, Version: NP—004439.1, GI:4758298, PRI date: Oct. 14, 1999, pp. 1-4.
Verma et al., Nature (1997) 389:239-242.
Amalfitano et al., Current Gene Therapy (2002) 2:111-133.
Pandha et al., Current Opinion in Investigational Drugs (2000) 1:122-134.
Houdebine, Journal of biotechnology (1994) 34:269-287.
Database EMBL [Online] Accession No. AK024899 (Sep. 29, 2000).
Database Geneseq [Online] Accession No. ADE56103 (Jan. 29, 2005).
Challita-Eid Pia M.
Faris Mary
Hubert Rene S.
Jakobovits Aya
Morrison Karen Jane Meyrick
Agensys, Inc.
Duffy Brad
Morrison & Foerster / LLP
Rawlings Stephen L.
LandOfFree
Nucleic acid and corresponding protein entitled 161P2F10B... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid and corresponding protein entitled 161P2F10B..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid and corresponding protein entitled 161P2F10B... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3833565